Learn what GLP-1 receptor agonists are, how the incretin hormone GLP-1 regulates appetite and blood sugar, and why these medications have transformed obesity medicine.
標籤彙整: obesity
Who Is a Candidate for GLP-1 RA Medications? BMI Thresholds, Comorbidities, and FDA Approvals
Understand the BMI and comorbidity criteria for Wegovy and Zepbound eligibility, contraindications, and what medical evaluation is required before starting GLP-1 RA therapy.
GLP-1 RA for Type 2 Diabetes vs. Obesity: Understanding the Difference Between Ozempic, Wegovy, Mounjaro, and Zepbound
Clarify the differences between Ozempic, Wegovy, Mounjaro, and Zepbound: same molecules, different doses, different FDA indications, and what that means for prescribing and insurance coverage.
Gout and Metabolic Syndrome: The Interconnection of Uric Acid, Obesity, and Lipids
Investigate the relationship between hyperuricemia, insulin resistance, visceral obesity, and dyslipidemia in patients with gout.
Weight Regain After Stopping GLP-1 RA: The Biology of Rebound and Long-Term Management Strategies
After stopping semaglutide or tirzepatide, most patients regain significant weight within 1–2 years. Learn the biology behind rebound, what STEP 4 trial data shows, and strategies for long-term weight maintenance.
不吃早餐與過重及肥胖有關！
就我個人所知，過去一直在爭論到底吃不吃早餐，跟肥胖有沒有關係，難得看到一篇系統性回顧與統合分析，覺得很有趣，分繼續閱讀 “不吃早餐與過重及肥胖有關！”